Prophylactic transfer of BCR-ABL–, PR1-, and WT1-reactive donor T cells after T cell–depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia
Martin Bornhäuser(Technische Universität Dresden), Marc Schmitz(Berlin-Brandenburger Centrum für Regenerative Therapien), Hanka Jähnisch(Technische Universität Dresden), Christian Thiede(University Hospital Carl Gustav Carus), Doris Lehmann, Gerhard Ehninger(University Hospital Carl Gustav Carus), Uta Oelschlaegel(University Hospital Carl Gustav Carus), Alexander Kiani(Bayreuth Medical Center), Martin Wermke(National Center for Tumor Diseases), Michael Bachmann(Heidelberg University), Kristina Hölig(German Red Cross), Jana Babatz, Uwe Platzbecker(National Center for Tumor Diseases), Sebastian Tuve, E. Peter Rieber(Innsbruck Medical University), Rebekka Wehner(Technische Universität Dresden), Jörgen Radke, Johannes Schetelig(University Hospital Carl Gustav Carus)
Cited by 50
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k